The endovascular approach for in-stent restenosis in femoropopliteal disease

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 4, 2015, Pages 391-401

  Cannavale, Alessandro ^a   Tsetis, Dimitrios ^b   Krokidis, Miltiadis ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

angioplasty; in stent restenosis; peripheral vascular disease; stent

Indexed keywords

BARE METAL STENT; CARDIOVASCULAR STENT; CLINICAL EFFECTIVENESS; COVERED STENT; DRUG ELUTING BALLOON ANGIOPLASTY; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; FEMOROPOPLITEAL IN STENT RESTENOSIS; HUMAN; IN-STENT RESTENOSIS; LEG DISEASE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; PLAIN OLD BALLOON ANGIOPLASTY; POPLITEAL ARTERY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPERFICIAL FEMORAL ARTERY; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT INDICATION; ANGIOPLASTY; FEMORAL ARTERY; GRAFT OCCLUSION, VASCULAR; PERIPHERAL ARTERIAL DISEASE; PROCEDURES;

ANGIOPLASTY; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; FEMORAL ARTERY; GRAFT OCCLUSION, VASCULAR; HUMANS; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY;

EID: 84925334727     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1023293     Document Type: Review

References (68)

1. Tendera M, Aboyans V, Bartelink ML, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2851-906
2. Katsanos K, Tepe G, Tsetis D, et al. Standards of practice for superficial femoral and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol 2014;37:592-603
3. Singh GD, Armstrong EJ, Laird JR. Femoropopliteal in-stent restenosis: current treatment strategies. J Cardiovasc Surg (Torino) 2014;55:325-33
4. Yahagi K, Otsuka F, Sakakura K, et al. Pathophysiology of superficial femoral artery in-stent restenosis. J Cardiovasc Surg (Torino) 2014;55:307-23
5. Nikanorov A, Schillinger M, Zhao H, et al. Assessment of self-expanding nitinol stent deformation after chronic implantation into the femoropopliteal arteries. EuroIntervention 2013;9:730-7
6. El-Sayed HF. Endovascular techniques in limb salvage: stents. Methodist Debakey Cardiovasc J 2013;9:79-83
7. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 2012;59:16-23
8. Zeller T, Tiefenbacher C, Steinkamp HJ, et al. Nitinol stent implantation in TASC A and B superficial femoral artery lesions: the Femoral Artery Conformexx Trial (FACT). J Endovasc Ther 2008;15:390-8
9. Davaine JM, Azema L, Guyomarch B, et al. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA"Stenting Long De L'Artere femorale superficielle"cohort). Eur J Vasc Endovasc Surg 2012;44:432-41
10. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 2012;19:1-9
11. Chalmers N, Walker PT, Belli AM, et al. Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol 2013;36:353-61
12. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007;115:2745-9
13. Geraghty PJ, Mewissen MW, Jaff MR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg 2013;58:386-95
14. Lammer J, Zeller T, Hausegger KA, et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol 2013;62:1320-7
15. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61: 2417-27
16. Katsanos K, Spiliopoulos S, Karunanithy N, et al. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg 2014;59:1123-33
17. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology 2008;248:297-302
18. Beschorner U, Krankenberg H, Scheinert D, et al. Rotational and aspiration atherectomy for infrainguinal in-stent restenosis. Vasa 2013;42:127-33
19. Shammas NW, Shammas GA, Jerin M. Differences in patient selection and outcomes between SilverHawk atherectomy and laser ablation in the treatment of femoropopliteal in-stent restenosis: a retrospective analysis from a single center. J Endovasc Ther 2013;20:844-52
20. Yeo KK, Malik U, Laird JR. Outcomes following treatment of femoropopliteal in-stent restenosis: a single center experience. Catheter Cardiovasc Interv 2011;78:604-8
21. Shammas NW, Shammas GA, Hafez A, et al. Safety and one-year revascularization outcome of excimer laser ablation therapy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. Cardiovasc Revasc Med 2012;13:341-4
22. Laird Jr. Jr, Yeo KK, Rocha-Singh K, et al. Excimer laser with adjunctive balloon angioplasty and heparin-coated selfexpanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. Catheter Cardiovasc Interv 2012;80: 852-9
23. Schmidt A, Zeller T, Sievert H, et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. J Endovasc Ther 2014;21: 52-60
24. Werner M, Scheinert D, Henn M, et al. Endovascular brachytherapy using liquid Beta-emitting rhenium-188 for the treatment of long-segment femoropopliteal in-stent stenosis. J Endovasc Ther 2012;19: 467-75
25. Shin SH, Baril DT, Chaer RA, et al. Cryoplasty offers no advantage over standard balloon angioplasty for the treatment of in-stent stenosis. Vascular 2013. [Epub ahead of print]
26. Al Shammeri O, Bitar F, Ghitelman J, et al. Viabahn for femoropopliteal in-stent restenosis. Ann Saudi Med 2012;32:572-82
27. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv 2013;6:274-81
28. Leopardi M, Houbballah R, Becquemin JP. Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis. J Cardiovasc Surg (Torino) 2014;55: 229-34
29. Armstrong EJ, Singh S, Singh GD, et al. Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-Term outcomes after endovascular intervention. Catheter Cardiovasc Interv 2013;82:1168-74
30. Krokidis M, Spiliopoulos S, Katsanos K, et al. Peripheral applications of drug-coated balloons: past, present and future. Cardiovasc Intervent Radiol 2013;36: 281-91
31. Montorsi P, Galli S, Fabbiocchi F, et al. Randomized trial of conventional balloon angioplasty versus cutting balloon for in-stent restenosis. Acute and 24-hour angiographic and intravascular ultrasound changes and long-Term follow-up. Ital Heart J 2004;5:271-9
32. De Labriolle A, Pakala R, Bonello L, et al. Paclitaxel-eluting balloon: from bench to bed. Catheter Cardiovasc Interv 2009;73: 643-52
33. Pósa A, Nyolczas N, Hemetsberger R, et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv 2010;76:395-403
34. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel coated balloon catheter. N Engl J Med 2006;355:2113-24
35. Hehrlein C, Dietz U, Kubica J, et al Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER trial. Cardiovasc Revasc Med 2012;13: 260-4
36. Navarese EP, Austin D, Gurbel PA, et al. Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. Clin Res Cardiol 2013;102:279-87
37. Windecker S, Kolh P, Alfonso F, et al 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC and the European Association for Cardio-Thoracic Surgery (EACTS Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-619
38. Liistro F, Angioli P, Porto I, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther 2014;21:1-8
39. Milewski K, Afari ME, Tellez A, et al. Evaluation of efficacy and dose response of different paclitaxel-coated balloon formulations in a novel swine model of iliofemoral in-stent restenosis. JACC Cardiovasc Interv 2012;5:1081-8
40. Buszman PP, Tellez A, Afari ME, et al. Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model. JACC Cardiovasc Interv 2013;6:883-90
41. Fanelli F, Cannavale A, Corona M, et al The"DEBELLUM"-lower limb multilevel treatment with drug eluting balloon-randomized trial: 1-year results. J Cardiovasc Surg (Torino) 2014;55:207-16
42. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118:1358-65
43. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-99
44. Stabile E, Virga V, Salemme L, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol 2012;60:1739-42
45. Virga V, Stabile E, Biamino G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv 2014;7:411-15
46. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv 2013;6: 1295-302
47. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014;7:10-19
48. Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg 2013;58:682-6
49. Van den Berg JC, Pedrotti M, Canevascini R, et al. In-stent restenosis: mid-Term results of debulking using excimer laser and drug-eluting balloons: sustained benefit?. J Invasive Cardiol 2014;26:333-7
50. Yang X, Lu X, Li W, et al. Endovascular treatment for symptomatic stent failures in long-segment chronic total occlusion of femoropopliteal arteries. J Vasc Surg 2014;60:362-8
51. Neil N. Stent fracture in the superficial femoral and proximal popliteal arteries: literature summary and economic impacts. Perspect Vasc Surg Endovasc Ther 2013;25: 20-7
52. Monahan TS, Vartanian S, Schneider DB. Effective treatment of femoropopliteal in-stent restenosis with stent grafts. J Vasc Surg 2011;54:917-18
53. Gorgani F, Telis A, Narakathu N, et al. Long-Term outcomes of the Viabahn stent in the treatment of in-stent restenosis in the superficial femoral artery. J Invasive Cardiol 2013;25:670-4
54. Fusaro M, Cassese S, Ndrepepa G, et al. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. JACC Cardiovasc Interv 2013;6:1284-93
55. Fanelli F, Cannavale A. Endovascular treatment of infrapopliteal arteries: angioplasty vs stent in the drug-eluting era. Eur Radiol 2014;24:793-8
56. Tsetis D, Belli AM, Morgan R, et al. Preliminary experience with cutting balloon angioplasty for iliac artery in-stent restenosis. J Endovasc Ther 2008;15: 193-202
57. Davies MG, Anaya-Ayala JE. Endovascular techniques in limb salvage: cutting, cryo, brachy, and drug-eluting balloons. Methodist Debakey Cardiovasc J 2013;9: 69-72
58. Cioppa A, Stabile E, Popusoi G, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: one-year single centre clinical results. Cardiovasc Revasc Med 2012;13: 219-23
59. Gandini R, Del Giudice C, Merolla S, et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther 2013;20:805-14
60. Directional AthErectomy followed by a PaclItaxel-coated BallooN to InhibiT RestenosIs and maintain vessel PatEncy: a pilot study of anti-restenosis treatment. Available from: http://clinicaltrials.gov/ct2/rtshow/record/NCT01366482
61. Van Den Berg JC, Pedrotti M, Canevascini R, et al. Endovascular treatment of in-stent restenosis using excimer laser angioplasty and drug eluting balloons. J Cardiovasc Surg (Torino) 2012;53: 215-22
62. Deloose K. RELINE-randomized clinical trial: Viabahn covered stents vs. PTA. Presented at The Leipzig Interventional Course-LINC 2014; 28-31 January 2014 Leipzig, Germany
63. Cannavale A, Krokidis M. The role of drug-eluting balloons for the in-stent restenosis in femoro-popliteal interventions. Ital J Vasc Endovasc Surg 2014;21:183-9
64. Palena LM, Manzi M. Direct stent puncture technique for intraluminal stent recanalization in the superficial femoral and popliteal arteries in-stent occlusion: outcomes from a prospective clinical analysis of diabetics with critical limb ischemia. Cardiovasc Revasc Med 2013;14:203-6
65. Diamantopoulos A, Katsanos K, Spiliopoulos S, et al. Subintimal recanalization of occluded stents: the substent technique. Cardiovasc Intervent Radiol 2013;36:943-9
66. Randomized trial of IN.PACT Admiral (TM) Drug Eluting Balloon vs Standard PTA for the Treatment of SFA and proximal popliteal arterial disease (INPACT SFA I). ClinicalTrials.gov identifier: NCT01175850. Available from: https://clinicaltrials.gov/ct2/show/NCT01175850'erm=NCT01175850&rank=1
67. ClinicalTrials.gov identifier: NCT01330628 Standard balloon angioplasty versus angioplasty with a paclitaxel-eluting balloon for femoral artery in-stent restenosis (FAIR)Available from
68. Randomized study of laser and balloon angioplasty versus balloon angioplasty to treat peripheral in-stent restenosis (EXCITE ISR). ClinicalTrials.gov identifier: NCT01330628. Available from: https://clinicaltrials.gov/ct2/show/NCT01330628'term=EXCITE+ISR&rank=1